DelSite Biotech Prepares To Test Powder Bird Flu Vaccine

Tag it:

DelSite Biotechnologies Inc, a subsidiary of Carrington Labs, has recently received a large delivery of the H5N1 strain antigen. The H5N1 is more commonly known the most common strain of the avian flu.
 
DelSite intends to unite the antigen with the dry powder system that the company has developed, and already successfully tested.
 
If the bird flu vaccine can be given in a dry powder form, it could solve a couple of the challenges facing organizations trying to provide the vaccine widespread across the world, in preparation for a pandemic.
 
One problem that would be reduced would be the potential for storing the vaccine in countries without decent refrigeration practices, since a powder vaccine wouldn't need to be kept cold.
 
Also a powder vaccine administered through the nose would cut down on costs of medical personnel, since people could self-administer the vaccine nasally.
 
More information is available at www.carringtonlabs.com
 

Tag it:

Tags:

Click to add your tags...,

or Close

Comments (0) >>

Write comment

You must be logged in to a comment. Please register if you do not have an account yet.